Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014;10(11):3175-8.
doi: 10.4161/hv.29418.

Peptide-based vaccines for cancer therapy

Giorgio Parmiani  1 , Vincenzo Russo, Cristina Maccalli, Danilo Parolini, Nathalie Rizzo, Michele Maio
Affiliations
Review

Peptide-based vaccines for cancer therapy

Giorgio Parmiani et al. Hum Vaccin Immunother. 2014.

Abstract

Interest for cancer vaccination started more than 30 years ago after the demonstration that both in animal models and later on in patients it is possible to generate anti-tumor immune responses. The clinical application of this knowledge, however, was disappointing. In this review we summarize results on peptides epitopes recognized by T cells that have been studied thanks to their easy synthesis and the lack of significant side effects when administered in-vivo. To improve the clinical efficacy, peptides were modified in their aminoacid sequence to augment their immunogenicity. Peptides vaccines were recently shown to induce a high frequency of immune response in patients that were accompanied by clinical efficacy. These data are discussed at the light of recent progression of immunotherapy caused by the addition of check-point antibodies thus providing a general picture of the potential therapeutic efficacy of the peptide-based vaccines and their combination with other biological agents.

Keywords: antigens; cancer; epitopes; immune responses; vaccination.

PubMed Disclaimer

References

    1. Prehn RT, Main JM. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 1957; 18:769-78; PMID:13502695 - PubMed
    1. Duan F, Lin Y, Liu C, Engelhorn ME, Cohen AD, Curran M, Sakaguchi S, Merghoub T, Terzulli S, Wolchok JD, et al. . Immune rejection of mouse tumors expressing mutated self. Cancer Res 2009; 69:3545-53; PMID:19351857; http://dx.doi.org/10.1158/0008-5472.CAN-08-2779 - DOI - PMC - PubMed
    1. Parmiani G, Pilla L, Maccalli C, Russo V. Autologous versus allogeneic cell-based vaccines? Cancer J 2011; 17:331-6; PMID:21952283; http://dx.doi.org/10.1097/PPO.0b013e3182337a76 - DOI - PubMed
    1. Marchand M, Weynants P, Rankin E, Arienti F, Belli F, Parmiani G, Cascinelli N, Bourlond A, Vanwijck R, Humblet Y, et al. . Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 1995; 63:883-5; PMID:8847150; http://dx.doi.org/10.1002/ijc.2910630622 - DOI - PubMed
    1. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254:1643-7; PMID:1840703; http://dx.doi.org/10.1126/science.1840703 - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources